Related Experiment Video
Updated: May 8, 2026
Comparative Lesions Analysis Through a Targeted Sequencing Approach
Published on: November 5, 2019
Genomic insights into molecular profiling of thymic carcinoma: a narrative review
1Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Background And Objective:
Thymic carcinoma is an exceptionally rare cancer, with an annual incidence of just 0.15-0.29 per 100,000 people. Owing to its rarity, only few proven treatments have been developed. Understanding its genetic profile is crucial for the development of targeted therapies. However, limited studies have exclusively examined thymic carcinoma mutations, with most investigation combining thymomas and thymic carcinomas. This paper reviews findings from genetic studies focusing on thymic carcinoma alone and compares them to those of thymoma.
Methods:
We conducted a PubMed search for relevant English studies on thymic carcinoma genomics. Then, key papers utilizing target sequencing or whole-exome sequencing were analyzed.
Key Content And Findings:
The most frequently mutated genes were TP53, CDKN2A, CDKN2B, CYLD, KIT, TET2, SETD2, BAP1, and ASXL1. TP53 and CDKN2A are correlated with poor prognosis. CYLD, which regulates signaling related with proliferation and interacts with AIRE expression and T cell development, might predict the immunotherapy response. KIT mutations might enable targeted therapy. TET2, SETD2, BAP1, and ASXL1 regulate epigenetics, suggesting disruption of these mechanisms. Higher tumor mutational burden (TMB) and 16q loss distinguish thymic carcinoma from thymoma. Although some copy number aberrations are shared, thymic carcinoma exhibits a mutational profile distinct from that of thymoma.
Conclusions:
Thymic carcinoma demonstrates a unique genomic landscape, suggesting a molecular pathogenesis distinct from that of thymoma. Our findings revealed prognostic biomarkers such as TP53/CDKN2A and potential therapeutic targets such as KIT. Because thymic carcinoma is extremely rare, sharing molecular profiling data could provide valuable insights into the molecular mechanisms driving the development of these tumors.
Insights
Thymic carcinoma has a unique genetic profile, distinct from thymoma, with key mutations like TP53 and CDKN2A impacting prognosis. Understanding these genomic alterations is vital for developing targeted therapies for this rare cancer.
Area of Science:
- Oncology
- Genomics
- Cancer Research
Background:
- Thymic carcinoma is an exceptionally rare cancer with limited treatment options due to insufficient understanding of its genetic basis.
- Existing research often combines thymic carcinoma with thymoma, hindering specific insights into thymic carcinoma's unique molecular characteristics.
- Identifying genetic profiles is crucial for developing targeted therapies for thymic carcinoma.
Purpose of the Study:
- To review and analyze genetic studies focusing exclusively on thymic carcinoma.
- To compare the genomic landscape of thymic carcinoma with that of thymoma.
- To identify potential prognostic biomarkers and therapeutic targets in thymic carcinoma.
Main Methods:
- Conducted a PubMed search for English-language studies on thymic carcinoma genomics.
- Analyzed key papers that utilized target sequencing or whole-exome sequencing.
- Compared mutation profiles and copy number aberrations between thymic carcinoma and thymoma.
Main Results:
- Frequently mutated genes in thymic carcinoma include TP53, CDKN2A, CDKN2B, CYLD, KIT, TET2, SETD2, BAP1, and ASXL1.
- TP53 and CDKN2A mutations are associated with poor prognosis; KIT mutations may indicate targeted therapy potential; CYLD may predict immunotherapy response.
- Thymic carcinoma exhibits distinct genomic features, including higher tumor mutational burden and 16q loss, differentiating it from thymoma.
Conclusions:
- Thymic carcinoma possesses a unique genomic landscape, suggesting a distinct molecular pathogenesis compared to thymoma.
- TP53/CDKN2A and KIT represent significant prognostic biomarkers and potential therapeutic targets, respectively.
- Sharing molecular profiling data is essential for advancing research into the mechanisms driving thymic carcinoma development due to its rarity.
Related Concept Videos
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...